Folate Deficiency Anemia

Folate (folic acid, vitamin B9) deficiency impairs DNA synthesis in the same way as vitamin B12 deficiency, producing a megaloblastic, macrocytic anemia that is hematologically indistinguishable from B12 deficiency on the CBC and peripheral smear alone. The critical distinguishing feature is that folate deficiency does not cause the neurologic complications of B12 deficiency — and giving folic acid to a patient who actually has unrecognized concurrent B12 deficiency can correct the anemia while the B12-related neurologic damage continues to progress, potentially permanently. Because of this, every patient started on folic acid for a megaloblastic anemia needs B12 deficiency actively excluded or treated first, not simply assumed absent.^[1]

Presentation

Fatigue, pallor, and glossitis, with macrocytic anemia on the CBC — the same hematologic picture as B12 deficiency. Folate deficiency does not, by itself, cause the paresthesias, gait disturbance, or cognitive change seen in B12 deficiency — the presence of neurologic findings in a megaloblastic anemia should prompt evaluation for B12 deficiency, not be attributed to folate deficiency.

• Inadequate dietary intake — folate is present in dark green leafy vegetables, fruit, nuts, beans, and foods that also contain B12 (meat, fish, poultry, eggs, dairy).
• Chronic excessive alcohol intake — both reduces intake and impairs folate metabolism.
• Malabsorption syndromes, including celiac disease and inflammatory bowel disease.
• Increased folate demand: pregnancy, chronic hemolytic anemia, exfoliative skin disease, or high cell-turnover states.
• Medications that cause folate deficiency or antagonize folate: methotrexate, phenytoin, sulfasalazine, and other folate antagonists.
• Hemodialysis, which removes folate.

Laboratory evaluation

• Serum folate is prone to short-term fluctuation with recent dietary intake and can be misleading on its own.
• RBC folate reflects time-averaged folate status over the preceding red cell lifespan and is a more reliable indicator of true tissue folate adequacy than a single serum level.
• Always check, or ensure recent confirmation of, vitamin B12 status before or at the same time as diagnosing folate deficiency — the two commonly coexist, and folate deficiency must never be treated in isolation without knowing the B12 status.^[1]
• Macrocytosis (MCV over 100 fL) with hypersegmented neutrophils on peripheral smear supports megaloblastic anemia but does not distinguish folate from B12 deficiency as the cause.

• Correct hemoglobin and macrocytosis to normal.
• Meet increased folate demand (pregnancy, hemolysis, methotrexate therapy) without ever masking an unrecognized concurrent B12 deficiency.
• Prevent neural tube defects when folic acid is given prophylactically in pregnancy.

• Restoring normal dietary folate intake (dark green leafy vegetables, fruit, nuts, beans, and animal-source foods that also contain B12) may be sufficient for mild dietary deficiency without an ongoing increased demand.
• Reduce or stop excessive alcohol intake where this is a contributing factor.
• All patients of reproductive potential who could become pregnant should be counselled on routine folic acid prophylaxis independent of any current deficiency, given the time-critical window (neural tube closure occurs very early in pregnancy, often before pregnancy is recognized).

Breastfeeding: folate passes into breast milk and is compatible with breastfeeding; standard prophylactic supplementation typically continues throughout lactation.

Renal impairment (hemodialysis)

Folate is removed by dialysis; patients on chronic hemodialysis often need ongoing folic acid supplementation to prevent deficiency.

Expect a reticulocyte response within 3-4 days of starting effective therapy, with hemoglobin improving by about day 10 and full resolution within about 2 months, similar to the timeline for B12 deficiency. Continue treatment for as long as the underlying increased demand persists (pregnancy, hemolysis, ongoing methotrexate therapy) or until dietary deficiency is durably corrected.

1. Confirm adherence to the prescribed folic acid dose.
2. Recheck vitamin B12 status — an unrecognized or inadequately treated concurrent B12 deficiency is the most important cause of an apparently inadequate response, and continuing to escalate folic acid without addressing this risks allowing neurologic B12 complications to progress.
3. Screen for a different or concurrent cause of macrocytic anemia (medication effect, hypothyroidism, liver disease, myelodysplastic syndrome) if B12 and folate are both adequately addressed and the response remains inadequate.
4. Confirm the increased-demand indication (pregnancy, hemolysis, methotrexate) is still being accounted for in the dose.

• Giving folic acid to a patient with a megaloblastic anemia without first checking or treating B12 status — this is the single most important error in this chapter; it can mask the blood count response of B12 deficiency while its neurologic complications continue to progress.^[1]
• Empirically supplementing folate in a patient known to be at risk of B12 deficiency who is not also being treated for it.
• Using a single serum folate level to rule out deficiency when it is discordant with the clinical picture — consider RBC folate instead.
• Substituting L-methylfolate (a distinct product approved for antidepressant augmentation in major depressive disorder, not for treating confirmed folate-deficiency anemia) for standard folic acid — the two are not interchangeable, and L-methylfolate has not been established as routine folate-deficiency-anemia therapy.
• Using the standard 0.4 mg average-risk prophylactic dose in a pregnancy that actually meets higher-risk criteria for a folic acid-sensitive anomaly.

How to use this table: Doses are adult doses and require patient-specific confirmation. Select the drug name to open its complete Pharmasist Drug Database page. Never start folic acid for a megaloblastic anemia without confirming vitamin B12 status first — see Vitamin B12 Deficiency Anemia.

Folic acid (vitamin B9)

The oral route is sufficient to correct folate deficiency, even in patients with malabsorption syndromes. An IV formulation exists for fasting inpatients but is rarely needed.

Evidence note: Drug inventory, dosing, adverse effects, and comments reflect current practice per the British Society for Haematology cobalamin/folate guideline and the 2021 SOGC folic acid guideline.^[1][2]